Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Hanwella, Raveen ^a   Senanayake, Madhri ^a   de Silva, Varuni ^a  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ARTICLE; ATTENTION DEFICIT DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; EFFECT SIZE; HUMAN; META ANALYSIS; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT RESPONSE; ADOLESCENT; CHILD; COMPARATIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; METHYLPHENIDATE; PROPYLAMINES; TREATMENT OUTCOME;

EID: 80755159387     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-176     Document Type: Article

References (45)

1. Biederman J. Attention-deficit/hyperactivity disorder: A selective overview. Biol Psychiatry 2005, 57:1215-1220. 10.1016/j.biopsych.2004.10.020, 15949990.
2. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/Hyperactivity Disorder. Biol Psychiatry 2011, 69(12):e145-57. 10.1016/j.biopsych.2011.02.036, 21550021.
3. American Association of Pediatrics Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. American Academy of Pediatrics. Pediatrics 2000, 105(5):1158-1170. American Association of Pediatrics.
4. Centers for Disease Control and Prevention Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder--United States, 2003. MMWR Morb Mortal Wkly Rep 2005, 54(34):842-847. Centers for Disease Control and Prevention.
5. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2(2):104-113. 1525078, 16946912.
6. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999, 56(12):1073-1086. 10.1001/archpsyc.56.12.1073, 10591283, MTA Cooperative Group.
7. Newcorn JH. Advances in the Management of Attention-Deficit/Hyperactivity Disorder: An Evidence-Based Update. Managed Care Consultant 2007, 6(2).
8. Kavale K. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis. J Learn Disabil 1982, 15(5):280-289. 10.1177/002221948201500508, 6123539.
9. Thurber S, Walker CE. Medication and hyperactivity: a meta-analysis. J Gen Psychol 1983, 108(1st Half):79-86.
10. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat 2009, 5:215-226. 2695220, 19557116.
11. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996, 35(10):1314-1321. 10.1097/00004583-199610000-00018, 8885585.
12. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004, 24(1):24-29. 10.1097/01.jcp.0000108984.11879.95, 14709943.
13. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006, 8(4):4. 1868385, 17415287.
14. Kratochvil CJ, Milton DR, Vaughan BS, Greenhill LL. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health 2008, 2(1):25. 10.1186/1753-2000-2-25, 2556311, 18793405.
15. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 2001, 165(11):1475-1488. 81663, 11762571.
16. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC, 4, American Psychiatric Association.
17. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA. Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol 1992, 45(3):255-265. 10.1016/0895-4356(92)90085-2, 1569422.
18. Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006, 29(12):1573-1585.
19. Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv Ther 2005, 22(5):498-512. 10.1007/BF02849870, 16418159.
20. Prasad S, Harpin V, Poole L, Zeitlin H, Jamdar S, Puvanendran K. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007, 23(2):379-394. 10.1185/030079906X167309, 17288692.
21. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002, 63(12):1140-1147. 10.4088/JCP.v63n1209, 12523874.
22. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV checklists, norms, and clinical interpretation 1998, New York: The Guilford Press.
23. Turgay Disruptive Behavior Disorders Child and Adolescent Screening and Rating Scales for Children, Adolescents, Parents, and Teachers 1994, West Blomfield: Integrative Therapy Institute Publication, Turgay.
24. The Nordic Cochrane Centre Review Manager (RevMan) [ComputerProgram] Version 5.0. 2008, Copenhagen: The Cochrane Collaboration, Version 5.0, The Nordic Cochrane Centre.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
26. Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Can J Clin Pharmacol 2006, 13(1):e50-62.
27. Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002, 41(7):776-784. 10.1097/00004583-200207000-00008, 12108801.
28. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008, 165(6):721-730. 10.1176/appi.ajp.2007.05091676, 18281409.
29. Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry 2007, 41(3):222-230. 10.1080/00048670601057767, 17464703.
30. Yildiz O, Sismanlar SG, Memik NC, Karakaya I, Agaoglu B. Atomoxetine and Methylphenidate Treatment in Children with ADHD: The Efficacy, Tolerability and Effects on Executive Functions. Child Psychiatry Hum Dev 2010,
31. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007, 194(2):197-209.
32. Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, Gelowitz DL. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45(8):919-927. 10.1097/01.chi.0000222788.34229.68, 16865034.
33. Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006, 40(6):1134-1142. 10.1345/aph.1G582, 16735655.
34. Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, van Wyk GW. Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate: A Direct Comparison Meta-Analysis. J Atten Disord 2010,
35. Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, et al. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 2005, 14(6):297-304. 10.1007/s00787-005-0467-6, 16220213.
36. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001, 107(6):E105. 10.1542/peds.107.6.e105, 11389303.
37. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108(4):883-892. 10.1542/peds.108.4.883, 11581440.
38. Favreau A, Deseille-Turlotte G, Brault F, Giraudeau B, Krier C, Barthez MA, Castelnau P. [Benefit of the extended-release methylphenidate formulations: a comparative study in childhood]. Arch Pediatr 2006, 13(5):442-448. 10.1016/j.arcped.2006.02.004, 16597499.
39. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007, 194(2):197-209.
40. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002, 159(11):1896-1901. 10.1176/appi.ajp.159.11.1896, 12411225.
41. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008, 121(2):e314-320. 10.1542/peds.2006-1880, 18245404.
42. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, Trzepacz PT, Allen AJ. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008, 47(2):209-18. 10.1097/chi.0b013e31815d88b2, 18176331.
43. Graham J, Coghill D. Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder Epidemiology, Prevention and Management. CNS Drugs 2008, 22(3):213-237. 10.2165/00023210-200822030-00003, 18278977.
44. Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011, 13(4):CD007990.
45. Higgins JPT, Green S, . Cochrane Collaboration Cochrane handbook for systematic reviews of interventions 2008, Chichester, England; Hoboken, NJ: Wiley-Blackwell, Cochrane Collaboration.